DATA GRAPHICS | Deals
Data Bytes: Bayer building women’s health portfolio
August 14, 2020 12:48 AM UTC
Bayer’s takeout of KaNDy Therapeutics Ltd. this week is the pharma’s third deal in women’s health this year. In the past decade, the company has closed at least seven R&D, M&A or in-licensing agreements in the field.
Bayer AG (Xetra:BAYN) is acquiring the menopause play for $425 million up front and up to $450 million in development milestones, plus undisclosed sales milestones in the triple digits (see “Single-asset KaNDy Finds Exit”)...